Generate Biomedicines, Inc.

Generate Biomedicines uses machine learning and artificial intelligence to design new protein-based drugs. The company is developing several experimental treatments, including GB-0895 for severe asthma (given as an injection every six months), GB-4362 for targeted cancer therapy, and GB-5267 as a CAR-T cell therapy (a type of cancer treatment that uses modified immune cells). The company's core technology platform combines computational design with lab equipment to create therapeutic proteins that would be difficult or impossible to develop using traditional methods.